Abstract
Ischemia and reperfusion injury (IRI) is a prime antigen-independent inflammatory factor in the dysfunction of liver transplants. Despite improved allograft preservation and surgical techniques, IRI can still cause up to 10% of early orthotopic liver transplant failure, and can lead to a higher incidence of both acute and chronic graft rejection. Recent advances in gene transfer have resulted in a reduction or inhibition of liver IRI in several experimental models. This review summarizes the development of existing and potential approaches to human gene therapy. These studies aimed at ameliorating I/R injury are focused on the cytoprotective effects in transplant recipients by induction of anti-apoptotic or protective genes, immunoregulation of cytokines or blockade of signaling transduction pathway in graft cells. Although this review focuses on the application of viral mediated gene therapy, new non-viral gene transfer techniques, such as RNA interference (RNAi) application, are discussed. Future advances in gene therapy technology should result in fewer side effects, and thus more acceptable for clinical application, and more successful for organ transplantation.
Keywords: Ischemia/Reperfusion Injury, Liver, Transplantation, Gene Therapy, Heme Oxygenase-1, Cytokines, Costimulation
Current Pharmaceutical Design
Title: Gene Therapy in Liver Ischemia and Reperfusion Injury
Volume: 12 Issue: 23
Author(s): Bibo Ke, Gerald S. Lipshutz and Jerzy W. Kupiec-Weglinski
Affiliation:
Keywords: Ischemia/Reperfusion Injury, Liver, Transplantation, Gene Therapy, Heme Oxygenase-1, Cytokines, Costimulation
Abstract: Ischemia and reperfusion injury (IRI) is a prime antigen-independent inflammatory factor in the dysfunction of liver transplants. Despite improved allograft preservation and surgical techniques, IRI can still cause up to 10% of early orthotopic liver transplant failure, and can lead to a higher incidence of both acute and chronic graft rejection. Recent advances in gene transfer have resulted in a reduction or inhibition of liver IRI in several experimental models. This review summarizes the development of existing and potential approaches to human gene therapy. These studies aimed at ameliorating I/R injury are focused on the cytoprotective effects in transplant recipients by induction of anti-apoptotic or protective genes, immunoregulation of cytokines or blockade of signaling transduction pathway in graft cells. Although this review focuses on the application of viral mediated gene therapy, new non-viral gene transfer techniques, such as RNA interference (RNAi) application, are discussed. Future advances in gene therapy technology should result in fewer side effects, and thus more acceptable for clinical application, and more successful for organ transplantation.
Export Options
About this article
Cite this article as:
Ke Bibo, Lipshutz S. Gerald and Kupiec-Weglinski W. Jerzy, Gene Therapy in Liver Ischemia and Reperfusion Injury, Current Pharmaceutical Design 2006; 12 (23) . https://dx.doi.org/10.2174/138161206777947669
DOI https://dx.doi.org/10.2174/138161206777947669 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hepatic Injury to the Newborn Liver Due to Drugs
Current Pharmaceutical Design Early Pathogenesis of Atherosclerosis: The Childhood Obesity
Current Pharmaceutical Design Redox Mechanisms of Vascular Cell Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
Current Medicinal Chemistry Caspases as Drug Targets in Ischemic Organ Injury
Current Drug Targets - Immune, Endocrine & Metabolic Disorders New Frontiers in the Management of Acute Coronary Syndromes: Cangrelor and Elinogrel
Recent Patents on Cardiovascular Drug Discovery Editorial: [Hot Topic: Recent Developments in Biomarker Patenting for AKI]
Recent Patents on Biomarkers Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Non-Alcoholic Steatohepatitis: New Insights from OMICS Studies
Current Pharmaceutical Biotechnology Active Immunization Against Tumor Necrosis Factor-alpha Decreases Proinflammatory Cytokines, Oxidative Stress Mediators and Adhesion Molecules Risk Factors in Streptozotocin-induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Myocardial Cellular Damage and Antioxidant Status in Off-Pump Versus On-Pump Coronary Artery Bypass Grafting - A Prospective Study
Vascular Disease Prevention (Discontinued) Isosteviol as a Starting Material in Organic Synthesis
Current Organic Chemistry Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury
Current Stem Cell Research & Therapy Guide of Hypertensive Crisis Pharmacotherapy
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Low-dose Tissue Plasminogen Activator is as Effective as Standard Tissue Plasminogen Activator Administration for the Treatment of Acute Ischemic Stroke
Current Neurovascular Research Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Looking for Organ Damages Due to Anabolic-androgenic Steroids (AAS): Is Oxidative Stress the Culprit?
Mini-Reviews in Organic Chemistry Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker for Acute Kidney Injury
Recent Patents on Biomarkers Pharmacological and Biological Activities of Xanthones
Anti-Infective Agents in Medicinal Chemistry